Skip to main content
Delfa

← Trials/Trial dossier/NCT00847860

CAVAD

CompletedPhase 4

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White

Assets

Aspirin / Cilostazol

Listed sites

2

Recruiting sites

-

Enrollment

200

actual

Study population

Vascular cognitive impairment / dementia, Mixed / unspecified dementia

Key I/E criteria

•Vascular or mixed dementia•MMSE 12-26

Primary endpoint

•Mini-Mental State Examination (MMSE)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00847860
Org study IDNeurology-2008-VD

Timeline

Milestones

Study start2008-03 (month precision)
Study first posted2009-02-19estimated
Primary completion2011-05actual (month precision)
Study completion2011-06actual (month precision)
Last update posted2015-05-06estimated

Assets

Drug assets

AspirinCilostazol

Study populations

Who this study enrolls

Vascular cognitive impairment / dementiaMixed / unspecified dementia

Eligibility

Who can enroll

Minimum age40 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Age ranging from 40 to 80 years

2. After newly ischemic stroke from 3 months to 2 years

3. Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)>=4

4. Moderate or mild cognitive deficits: MMSE 12-26

5. Vascular or mixed dementia: Hachinski ischemic score>4

6. Moderate or mild disability: MRS<=4,NIHSS<20

7. Informed consent

Exclusion criteria

1. Definitive diagnosis of dementia prior to the stroke

2. Cerebral hemorrhage in the past

3. Cerebral embolism result from cardiogenic embolus

4. Critically ills: MRS>4,NIHSS>=20

5. Bed-ridden patient who is hardly discovered newly stroke

6. patient with sever cardiac, hepatic or nephric complication

7. dementia caused not by vascular lesions

8. other diseases disturb the cognitive evaluation

9. susceptibility to varieties of allergen

10. abstain from Cilostazol or Asprin

11. antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases

12. rejected to participate by the patient or the family

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
1
Other (unclassified)
1

Global cognition

1 endpoint
Primary/protocol endpoint

changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth

Time frame:one year

Mini-Mental State Examination (MMSE)

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

stroke recurrence, other vascular ischemic events, bleeding events

Time frame:one year

event count, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.